Randomized Trialhigh evidence
Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease.
The New England journal of medicine·July 16, 2026·PMID 42456136
Why it mattersPatients with multivessel CAD remain at heightened ischemic risk after PCI, yet the optimal DAPT duration beyond 12 months is unclear. This trial provides evidence that extending clopidogrel-based DAPT for an additional year reduces ischemic events without a significant bleeding penalty in a stable, event-free population.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled